Starboard Value LP underperformed peers in 2024, a year in which Jeff Smith’s activist firm was frustrated with large ...

Activist investor Starboard Value has launched a broadside against Pfizer's leadership under chief executive Albert Bourla, claiming at least $20 billion in value – and possibly as much as $60 ...

Jeffrey Smith’s Starboard Value disclosed in an SEC filing its holdings as of December 31, 2024. The fund’s new buys during the fourth quarter ...

That drug came through Pfizer’s 2022 acquisition of Global Blood Therapeutics for US$5.4bil, one of a string of purchases that Starboard considers to have delivered poor results, the person said.

The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.

Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief ...

Pfizer got a reprieve in late January when Starboard did not nominate its own slate of directors to the company’s board, but the activist could still agitate for changes in 2026. Among Pfizer ...

Pfizer appears to have dodged a proxy battle with activist investor Starboard Value, which has a roughly $1 billion stake in the pharmaceutical giant, for now. The deadline passed for nominating ...

Director nominees with CEO experience have long featured in Board slates put forward by activist investors. Those candidates were typically from outs ...

Starboard Value LP bought a new stake in shares of Pfizer in the 4th quarter valued at $407,730,000. Raymond James Financial Inc. bought a new stake in shares of Pfizer in the 4th quarter valued ...